This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • Detailed results from Phase III COSMIC-311 pivotal...
News

Detailed results from Phase III COSMIC-311 pivotal trial of cabozantinib in for previously treated radioactive iodine-refractory differentiated thyroid cancer - Ipsen + Exelixis Inc.

Read time: 1 mins
Published:16th Jun 2021
Exelixis, Inc. and Ipsen announced detailed results from the phase III COSMIC-311 pivotal trial of cabozantinib (Cabometyx) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC). Results from the trial, which met the co-primary endpoint of significant improvement in progression-free survival (PFS) assessed by blinded independent radiology committee (BIRC), are in press to be published in The Lancet Oncology and have been submitted to the FDA.

 The data were presented during the Oral Abstract Session: Head and Neck Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract #6001). “Following disease progression on anti-VEGFR therapy, patients with radioactive iodine-refractory differentiated thyroid cancer currently have no standard of care available to them, making the positive results of the COSMIC-311 trial an important clinical advance for this community in need of additional treatment options,” said Marcia S. Brose, M.D., Ph.D., Full Professor of Otorhinolaryngology: Head and Neck Surgery and Director of the Center for Rare Cancers and Personalized Therapy at the Abramson Cancer Center of the University of Pennsylvania, and principal investigator of COSMIC-311. “The significant improvement in progression-free survival and favorable trend for overall survival suggest cabozantinib could be an important new option for these patients.” Results from COSMIC-311 served as the basis for the supplemental New Drug Application that Exelixis has submitted to the FDA, seeking an expanded indication for Cabometyx for patients 12 and older with DTC that has progressed following prior therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). As previously announced, at a planned interim analysis, cabozantinib demonstrated a significant reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22; 96% confidence interval [CI]: 0.13-0.36; P<0.0001) in the intent-to-treat (itt) population. at a median follow-up of 6.2 months, median pfs was not reached (96% ci: 5.7 months – not estimable) in patients treated with cabozantinib and was 1.9 months (96% ci: 1.8-3.6 months) for placebo. the data presented at the 2021 asco annual meeting demonstrate that hrs for pfs consistently favored cabozantinib over placebo for prespecified subgroups, including age less than 65 vs. greater than 65; prior treatment with lenvatinib (yes vs. no), and number of prior vascular endothelial growth factor receptor (vegfr)-targeting therapies (1 vs. 2). the results for the co-primary endpoint of objective response rate in the first 100 randomized patients after six months favored cabozantinib at 15% versus 0% for placebo, although this difference was not statistically significant (p="0.028)." in the itt population, a reduction in target lesion size was found in 76% of patients receiving cabozantinib versus 29% of patients receiving placebo; median overall survival was not reached in either treatment arm but favored cabozantinib (hr: 0.54; 95% ci: 0.27-1.11). the safety profile was consistent with that previously observed for cabozantinib and adverse events (aes) were managed with dose modifications. the discontinuation rate due to treatment-emergent aes was 5% for cabozantinib versus 0% for placebo. the most common (?5%) all-causality grade 3 or 4 aes with cabozantinib were palmar-plantar erythrodysesthesia (10%), hypertension (9%), fatigue (8%), diarrhea (7%) and hypocalcemia (7%). there were no treatment-related deaths per investigator.></0.0001)>

Condition: Thyroid Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights